S722 Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Active Ulcerative Colitis Receiving 16 Weeks Extended Induction Treatment Followed by 52 Weeks Maintenance Treatment in U-ACHIEVE/U-ACCOMPLISH Trials

Autor: Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. Higgins, Edward V. Loftus, Séverine Vermeire
Rok vydání: 2022
Předmět:
Zdroj: American Journal of Gastroenterology. 117:e505-e506
ISSN: 1572-0241
0002-9270
Databáze: OpenAIRE